Patents by Inventor Zhengrong Yu

Zhengrong Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugated Antisense Compounds for Use in Therapy
    Publication number: 20240165146
    Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
    Type: Application
    Filed: June 23, 2023
    Publication date: May 23, 2024
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
  • COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
    Publication number: 20220184112
    Abstract: The present disclosure provides compositions for enhanced intestinal absorption of oligomeric compounds.
    Type: Application
    Filed: November 9, 2021
    Publication date: June 16, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Justin Drew Searcy, Zhengrong Yu, Julie C. Ma, Yanfeng Wang, Kaustubh H. Kulkarni
  • Modulating apolipoprotein (a) expression
    Patent number: 11319536
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a). In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: May 3, 2022
    Assignee: Ionis Pharmacueticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
  • Conjugated Antisense Compounds for Use in Therapy
    Publication number: 20210169917
    Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 10, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
  • MODULATING APOLIPOPROTEIN (A) EXPRESSION
    Publication number: 20200362340
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions.
    Type: Application
    Filed: December 30, 2019
    Publication date: November 19, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
  • Compounds and methods for detecting oligonucleotides
    Patent number: 10752940
    Abstract: The present invention provides methods of detecting and/or quantitating a target oligonucleotide in a biological sample.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: August 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Sarah Greenlee, Zhengrong Yu, Thazha P. Prakash, John E. Matson
  • Modulating apolipoprotein (a) expression
    Patent number: 10557137
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: February 11, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
  • MODULATING APOLIPOPROTEIN (A) EXPRESSION
    Publication number: 20190136233
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: November 7, 2016
    Publication date: May 9, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
  • CONJUGATED ANTISENSE COMPOUNDS FOR USE IN THERAPY
    Publication number: 20190046555
    Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 14, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
  • ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B
    Publication number: 20170096662
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Application
    Filed: May 18, 2016
    Publication date: April 6, 2017
    Applicant: Kastle Therapeutics, LLC
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • COMPOUNDS AND METHODS FOR DETECTING OLIGONUCLEOTIDES
    Publication number: 20160281148
    Abstract: The present invention provides methods of detecting and/or quantitating a target oligonucleotide in a biological sample.
    Type: Application
    Filed: November 10, 2014
    Publication date: September 29, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Sarah Greenlee, Zhengrong Yu, Thazha P. Prakash, John E. Matson
  • Administering antisense oligonucleotides complementary to human apolipoprotein B
    Patent number: 9347061
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: May 24, 2016
    Assignee: Genzyme Corporation
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
    Publication number: 20120115926
    Abstract: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.
    Type: Application
    Filed: August 19, 2011
    Publication date: May 10, 2012
    Applicant: Genzyme Corporation
    Inventors: Richard S. Geary, Zhengrong Yu, Rosanne M. Crooke
  • Nuclease-based method for detecting and quantitating oligonucleotides
    Patent number: 8163477
    Abstract: A method for quantitating an oligonucleotide in a sample of bodily fluid and/or extract is provided. The method provides for the detection and/or localization of oligonucleotides, including administered modified oligonucleotides, for therapeutic and/or pharmacokinetic purposes.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: April 24, 2012
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: Zhengrong Yu, Brenda F. Baker, Hongjiang Wu
  • ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B
    Publication number: 20100297105
    Abstract: Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
    Type: Application
    Filed: March 24, 2008
    Publication date: November 25, 2010
    Applicant: GENZYME CORPORATION
    Inventors: Richard S. Geary, Zhengrong Yu, Mark K. Wedel, Diane Tribble
  • ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
    Publication number: 20090326040
    Abstract: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.
    Type: Application
    Filed: August 10, 2005
    Publication date: December 31, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Richard S. Geary, Zhengrong Yu, Rosanne M. Crooke
  • Methods for modulating lipoprotein and cholesterol levels in humans
    Publication number: 20060035858
    Abstract: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.
    Type: Application
    Filed: August 10, 2005
    Publication date: February 16, 2006
    Inventors: Richard Geary, Zhengrong Yu, Rosanne Crooke
  • Nuclease-based method for detecting and quantitating oligonucleotides
    Publication number: 20040005618
    Abstract: A method for quantitating an oligonucleotide in a sample of bodily fluid and/or extract is provided. The method provides for the detection and/or localization of oligonucleotides, including administered modified oligonucleotides, for therapeutic and/or pharmacokinetic purposes.
    Type: Application
    Filed: May 27, 2003
    Publication date: January 8, 2004
    Inventors: Zhengrong Yu, Brenda F. Baker, Hongjiang Wu
  • Method for quantitating oligonucleotides
    Patent number: 6355438
    Abstract: Methods and processes for quantitating the amount of oligonucleotide in a sample of bodily fluid and/or extract are provided. The methods and processes provided allow for the detection and/or localization of oligonucleotides for therapeutic and/or pharmacokinetic purposes by providing a highly sensitive assay that takes advantage of enzymes which recognize specific nucleic acid conformations and structures.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: March 12, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Zhengrong Yu, Janet M. Leeds